Azienda Ospedaliera Universitaria Federico II — Biomedical Watch V2

Essais liés7clinical trials

VilleNapleslocalisation

PaysItalylocalisation

SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07164443

Ouvrir le site du centre

Essais cliniques associés

7

Molécule	Indication / population	Phase	NCT	Titre	Statut
Maridebart cafraglutide	Insuffisance cardiaque	Phase 3	NCT07037459	MARITIME-HF — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity	RECRUITING
Elacestrant	Cancer	Phase 1/2	NCT05386108	ELECTRA — Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer	RECRUITING
RO7268489	SEP	Phase 2	NCT07282574	Mintaka — A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)	RECRUITING
Pasritamig	Cancer	Phase 3	NCT07164443	KLK2-comPAS — A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)	RECRUITING
Tacabrutideg	Cancer	Phase 3	NCT06846671	CaDAnCe-302 — A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors	RECRUITING
Giredestrant	Cancer	Phase 3	NCT06065748	A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)	ACTIVE_NOT_RECRUITING
Telitacicept	Myasthénie	Phase 3	NCT06456580	A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)	ACTIVE_NOT_RECRUITING